5-28. -...

7.CL References

® AcartOrk, F., Altug, N., 200i. In-vitro and in-vivo evaluation of a matrix-

controlied broiDOcriptine mesilate-releasing vaginal ring. J. Phanri. Pharmacol. 53

(12), ! 72M726.

<» Agnihotri, S.A., Mallikariuna, N.N., Aniinabhavi, T.M., 2004, Rect;nt: advances on

chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release iOO,

5-28.

® Agnihotri, S.M., Vavia, P.R., 2009, Diclofeiuic- loaded biopolyrneric

nanosuspensions for ophthalmic application. Nanomedicine: N.B.M, 5, 90-S)5.

® Aitkcn, M., Berndt, E.R., Cutler, D.M., 2009, Prescription drug spending trends in

the United States: looking beyo;nd the turning point. Heaitli Aff (Millwood).

28(1), 151- 160.

® AJun, W., Yan, S., Li, G., Huili, L., 2009. Preparation of aspirin and probuco! in

combination loaded chitosari nanoparticles and in vitro release study. Carbohyd.

Polym. 75, 566-574.

» Akbuga, .f,, Durraaz, G., 1994. Preparation and evaluation of crosslinked chitosan

microspheres containing furose:mide. In t..]. Pliarrn. I l l , 217-222.

• Aktas, Y., Andrieux, K., Alonso, M.f., Calvo, P., Gursoy, RN., Couvreur,

P., Capan, Y,, 2005. Preparation and in vitro evaluation of chitosan nanoparticles

containing a caspase inhibitor. I n t . P h a r m . 298(2), 378-83.

® Alam, M.I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Abuja, A.,

Akbar,M., 2010. Strategy for effective brain drug delivery. Eur. J. Pharm.

Sci, 40(5), 385-403

® Al-Ghananeem, A.M., Saeed, H., Florence, R., Yokel, R.A., Malkawi, A.H.,

2010. Intranasal drug delivery o f didanosine-loaded chitosan nanoparticles for

brain targeting; an attractive route against infections caused by aids viruses. J.

Drug. Target. 18: 381-388.

« Ali J, Ali M, Baboota S., 2010. Potential of nanoparticulate drug delivery Systems

by intranasal administration. Curr. Pharm. Des, 1644- 1653.

C hap ter 7 .Refereiice.s

Dept of Pliarniacewtics - Page 178

© Alsarra, I.A., Hamed, A.Y., Mahroiis, GJvl., Magliraby, Robayan, A.A.,

Alanazi, F.K., 2009. Miicoadhesive polymeric hydrogels for nasal delivery of

Acyclovir. Drug. FJev. Ind. Pharm. 35, 352-362.

® Aoyama, S., Kase, i l , Borrelli, E., 2000. Rescue of locomotor inipainnent in

dopamine D2 recept;or-deficient mice by an adenosine A2a receptor antagonist. J

Neurosci. 20, 5848--52.

B Artursson. P., Lindmark, T., Davis, SS,, 1994. Effect o f chitosan on the

permeability of irionolayers of intestinal epithelial ceils (Caco-2). Pharm Res. 11,

1358 -^1361.

e Avadi, MR., Sadeghi, A.M.M, Moharnmadpour, N., Abedin, S., Atyabi, F.,

f3inarvand, R., M. Rafiee-Tehrani, IVL, 2010. Preparation and characterization of

insulin nanoparticles using chitosan and Arabic gurn Vv'ith ionic gelation method,

Nanomed: Nanotech. Bioi. Med. 6, 58--63

® Babbar, A.K., Singh, K., Goef H.C., Chauha.n, U.S, Sharma, R.K., 2000.

Evaluation of 99mTc labeled Photosan-3, a heamatoporphyrin derivatii^e, as a

potential radiopharmaceutical for tumor scintigraphy. Nucl. Med. Biol. 27, 419-

426.

® Berger, J., Reist, M., Mayer, J.M., Felt, O., Peppas, N.A., Gurny, R., 2004,

Structure and interactions in covalently and ionically crtxsslinked chitosan

hydrogels for biomedical applications, Eur. J. Pharrn. Biopharm. 57, 19-34.

® Berthold, A., Cremer, K., Kreuter. .F., 1996. Preparation and characterization of

chitosan microspheres as drug carrier for prednisolone sodiinn phosphate a.s

model for anti-inflammatory drugs. J. Control. Rel. 39 (1), 17-25.

® Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-osuna, M., Panov, A.V.,

Greenamyre, .I.T., 2000. Chronic systemic pesticide exposure reproduces features

o f Parkinson’s disease. Nat, Neurosci. 3, i301-1306.

« Boonsongrit, Y., Mitrevej, A., Mueller, B.W., 2006. Chitosan drug binding

by ionic interaction, Eur .1 Pharm. Biopharm, 62(3), 267-74.

® Boonsongrit, Y., Mueller, B.W., Mitrevej, A., 2008, Characterization of drug-

chitosan interaction by IH NMR, FTIR and isothermal titration calorimetry. Eur.

J. Pharm. Biopharm. 69(3), 388-395.

Qtuipter 7___ _______ ___ __ __ References

Dept of Pharmaceutics Page 179

C hap ter 7 .References

Borlongan, C. V., Emerich, D.l-'., 2()03. Facilitation of drug entry into the CNS via

transient permeation of blood-brain barrier; laboratory aivd preiimiiiiir)'' clinical

evidence from bradykinin receptor agonist. Cerefjort, 13rain Res. Bull. 60, 297-

306.

Calvo, P., Goiiritin, B., Chacun, M,, 2001. Long-circulating PEGylated

polycyanoacry!al:c nanoparticles a.s new drug carrier for brain delivery. Pharm.

Res. 18, I ] 57-1166.

Calvo, P., Reinunan-Lopez, C., Vila-Jnta J.L,, Alonso, M.J,, 1997, Chitosan and

chitosan: ethylene oxide-propylene oxide block copolymer NPs as novel carriers

for proteins and vaccines, Phrani. Res. 14, i431--143<).

Campbell, M., Ozaki, IVI., Humphries, P., 2010. Systemic delivery of therapeirtic,s

to neuronal tissues; a barrier modulation approach. Expert. Opin. Drug. Deiiv. 7,

859-869.

Cai-vey, P.M., Ptak, L.R., Lin, D., Lo, E.S., Buhrfiend, C.M., Drucker, G.E.,

Fields, J.Z., 1993. Alterations in striatal neurotrophic activity induced by

dopaminergic drugs. Pharmacol Biochem Behav. 46 (1), 195-204.

Chang, W.H, Kao, C.H., Lin, C .I, Wang, S.J., 2007. Thermosensitive

nanostructure for hyperthermia treatment. US 20070154397.

Charlton, S., .fones, N.S., Davis, S.S., Ilium, L., 2007. Distribution and clearance

of bioadhesive formulations from the olfactory region in man; Effect of polymer

type and nasal delivery device. Eur. .1. Pharm. Sci. 30, 295-302.

Chen, L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W.,

Elastings, T.G., Kang, U.J., Zhuang, X., 2008. Unregulated cytosolic dopamine

causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28

(2), 425-433.

Chen, Y., Mohanraj, V..I, Wang, F., Benson, H.A., 2008. Desigining chitosan

dextran sulphate nanoparticles using charge ratio. AAPS Pharmscitech. S (4), 98-

105.

Chen, Y., Siddhalingappa, B, Chan PH., Benson, PLA., 2008. Development of

a chitosan-based nanoparticle formulation for delivery of a hydrophilic

hexapeptide, dalargin. Biopolymers. 90 (5), 663-670.

Bept of Pharmaceutics Page 180

» ChengLiang, L., Youlong, T., Chengslieng, L., Xiguang, C., Lejun, Y. 2()06.

Preparation, Cliaracterizatioii and application of cliitosan l:>ascd nanopaiticles. .1.

Ocean. Univcr. China, 6 (3), 237-243.

® C'henite, A., Busclirnann, M,, Wang, I),, Cliaput, C., Kandani N„ 2()01.

Rheological characterisation o f thennogelling chitosan/glyceroi-phosphate

solutions. Carboliyd. Polym. 46, 39-47.

ClH), K„ Wang, X., Nie, S., Chen, Z„ Shin, D.M., 2008. Tlierapeutic

nanoparticles for drug delivery in cancer. Ciiii. Cancer. Res, 14, 1310--13I6,

® Choi, Y., Sec, M., Kim, i , Lee, Y., 1997. High-performance liquid

chromatographic assay of bromocriptine in phisma and eye tissue o f the rabbit. .!.

Ciironiatography B. 694, 615-620.

0 Coi'bo, D.C., 1990. Characterization of the barrier properties o f mucosal

membranes. J, Pharm. Sci. 79, 202-206.

e Costantino, H.R., rilum, L„ Brandt, (}., Johnson, P.H., Quay, S.C., 2007.

Intrauasal delivery; Physicochemical and therapeutic aspects. Int. .1. Piianri. 337,

1-24.

o Crocker, A.D., Hemsley, K.M., 2001. An animal model of extrapyramidai side

effects induced by antipsychotic drugs: relationship with 132 dopamine receptor

occupancy. Prog Neuropsychopharmacoi Biol Psychiatry, 25, 573-590.

® Dahlin, M., Bjork, E., 2000. Nasal absorption of (S)-UH-301 and its transport into

the cerebrospinal fluid of rats. Int. J. Pharm. 195, 197-205.

® Dash, M., Chieliini, F., Ottenbrite, R.M., Chiellini, E., 2011. Chitosan~A versatile

semi-synthetic polyrtier in biomedical applications. Prog. Polym. Sci. 36, 981-

1014.

® De Campos, A. M., Sanchez, A., & Alonso, M. .1., 2001. Chitosan nanoparticles:

A new vehicle for the improvement of the delivery o f drugs to the ocular surface.

Application to cyclosporin A. Int. J. Phami. 224(1-2), 159-168.

® De Rosa, R., Garcia, A. A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N.,

Cattaneo, A., 2005, Intranasal administration o f nerve growth factor (NGF)

rescues recognition memory deficits in ADI 1 anti- NGF transgenic mice. Proc.

Natl. Acad. Sci,, 102 (10), 3811-3816,

C hapter 7 lleferences


© De Souza Silva M.A., Mattern, C., "ropic B, {luston, J.P., 2009. Dopainiiiergic and

serotonergic activity in neostriatum and nucleus accumbens enhanced by

intraiiasai administration of testosterone Eur Neuropsychophannacol, I 9, 53'-63.

e De Souza Silva M.A., Topic B, Huston, J.P., Mattern, C., .2008. Iritranasai

administration of progesterone increases dopaminergic activity in amygdala and

neostriatum of male rats. Neuroscience. 157 (1), 196-203.

® Degim, IT ., Acartiirk, F., Eirdogan, D., Lortlar, N.D., 2003. Transderma!

Administration of Bromocriptine. Ijio!. Phann. Bul l. 26(4), 501— .50.5.

o Desai, N.P., Soon-Shiong, P., Yang, A., 2007. Novel formulatioiis of

pharmacological agents, methods for the preparation thereof and methods for tiie

use thereof US2007009256.3.

s Devika, R.B., Varsha, B.P., 2006. Studies on Effect of pH on Cross-liiikirigj of

chitosan with Sodium Ti-ipolypliospliate; A Tecliiiical Note. AAPS Pharm. Sci.

Tech. 7 (2), 50-57.

© Dhanda, D., Frey, W.H., Leopold, D., Kompella, U.B., 2005. Nose-to-brain

delivery: approaches for drug deposition in the human olfactory epithelium. Drug

Delivery Technol, 4, 64-72.

e Dhuria, S.V., Hanson, L.R., Frey, W.H., 2010. Intranasa! delivery to the central

nervous system; Mechanism and experimental considerations. J. Pharm. Sci.

99(4), I654-1673.

e Dodane,V., Khan, M.A., Merwin, J.R., 1999. Effect o f chitosan on epithelial

permeability and structure. Int. J. Pharm. 182, 21 -32.

• Dorsey, E.R, Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G.,

Kieburtz, K., 2007. Projected nmnber of people with Parkinson disease in the

most populous nations, 2005 through 2030. Neurology. 68(5), 384-386.

• Drewe, J., Keck, M., Guitard, P., Pellet, A., Johnston, B., Beglinger, C., 1991.

Relevance of pH dependency on in vitro release of bromocriptine from a

modified-release formulation. J. Pharm. Sci. 80 (2), 160-163.

® Dudhani, A.R., Kosaraju, S.L., 2010. Bioadhesive chitosan NPs: Preparation and

characterization. Carbohyd. Polym. 81, 243-251,

C hapter 7 References

Bept of Pharmaceutics Page 182

® Dung, T.H., Lee, S.R., Han, S.D., Kim, S.J., Jii, Yi/L, K.im, K4.S., Yoo, M., 2007.

Chitosati- TPP nanopartick as a release system of antisense oligonucleotide in tlie

oral environment. J. Nanosci. Nariotecli. 7 (! 1), 3695-3699.

® Esposito, E Fantin, M., Marti, M., Drechsicr, M., Paccaniiccio, L., Mariani, P.,

2008. Solid iipicl iianoparticlcs a.s delivery systeriis for bromocriptine. Pharm. Res.

25 (7) 1521-1530.

® Esposito, E., Cortesi, R., Nastmzzi, C., 1996. Gelatin microspheres: influence of

preparation parameters and thermal treatment on chcmico-pliysical and

biopharniaceutical properties. Bioinater. 17 (20), 2009-2020.

9 Esposito, E., Mariani, P., Ravaiii, L., Contado, C., Voita, M., Bido, .S., Drechsler,

M., Mazzoni, S., Menegatti, E., Morari, M., Cortesi, R., 2012. Manoparticiiiate

lipid dispersions for bromocriptine delivery: Characterization and in vivo study.

Eur. J. Pharm. Biopharrn. 80 (2), 306-314.

• Esumi, K., Takei, N., & Yo,shimura, T., 2003. Antioxidant-potentiality of

goldchitosan nanocomposites. Colloids Surf Ei; Bioint. 32, 117-123.

® Fan, W., Yan W,, Xu, Z., Ni, FI. 2012. Formation mechanism of monodisperse,

low molecular weight chitosan naiioparticles by ionic gelation technique.

Colloids. SurfB. 90,21-27.

8 Fazil, M., Md, S., Haque, S., Sahni, J.K., Baboota, S., Ali, .1., 2012. Development

and Evaluation of Rivastigmine loaded Chitosan Nanopaiticles for Brain

Targeting. Eur. J. Pharm. Sci. 47: 6-15.

® Fernandez, M., Negro, S., Slowing, K., Fernandez-Carballido, A., Barcia, E.,

2011. An effective novel delivery strategy of rasagiline for Parkinson’s disease.

Int. J. Pharm. 419, 27F - 280.

® Fernandez, M..FA., Renninan Lopez, C., Cuna Vilan, M.M., Alonso Sande, M.,

2006. Nanoparticles for the administration of active ingredients, method of

producing said particles and composition containing same. US20060134785.

0 Fernandez-Urrusuno, R., Romani, D., Calvo, P., 1999. IDevelopment of a freeze

dried fonnidadon of insulin-loaded chitosan nanoparticles intended for nasal

administration, STP, Pharm. Sci. 5, 429-436.

Cluiipter 7 IRefereiices

Dept of Pliarmaceutlcs Page 183

e Florence, K., Maiiisha, L., Kuiriar, B.A.,Ankirr, K., K'umar,

M.A., Ambikanandan, M., 201 L intranasai clobazarn delivery in the treatrnent of

status epilepticus. J. Pharm. Sci. 100(2), 692-703.

» Fuciitc-Fernandez, R„ Schulzer, M., Mak, 11., Sossi, V., 2010. Trials of

neiiroprotcctive therapies ibr Parkinson's disease: problems and limitations,

Parkinsonism llelat. Disord. 16, 365 -369.

® Gan, ()., and Wang, T., 2007. Chitosan rsanoj3article as protein delivery carrier -

Systematic examination of fabrication conditions for efficient loading and release.

Coll. and Surface B: EJioint. 59, 24-34.

Gan, Q., Wang, T., Cochrane, C., & McCarron, P. 2005. Modulation of surface

charge, particle size and rnorphologica! properties of chitosan-TPP rianoparticles

intended for gene delivery. Colloids Surf, B: Bioint. 44(2-3), 65-73.

Gao, X., Chen, J., Tao, W., Zhu, J,, Zhang, Q., Chen, H., Jiang, X., 2007. UEA I-

bearing nanoparticles for brain delivery following intranasa! administration. Ii t. J.

Pharm. 340, 207-215.

• Gavini, E., Rassu, G., Sanna, V., Cossu, M., Giunchedi, P., 2005. Mucoadhesive

microspheres for nasal administration of an antiemetic drug, metoclopramide; in

\ntro/ex-vivo studies. J. Pharma. Pharmacol. 57, 287-294

« Go, C.L., Rosales, R.L., Schmidt, P, Lyoiis, K .fi, Pahvva, R., Okun., M.S., 2011.

Generic versus branded pharmacotherapy in Parkinson’s disease; Does it matter?

A review. Parkinsonism Relat. Disord. 17 (5), 308-312.

e Gozes, I , Eliezer, G., .foanna, M. H., Efrat, D., Conor, M.S., 2004.Vasoactive

Intestinal Peptide (VEP) Regukites Activity-Dependent Neuroprotective Protein

(ADNP) Expres.sion In Vivo. J. Mol. Nenrosci. 33(3), 278-283.

® Graff, C.L, Zhao, R., Pollack, G.M., 2005a. Pharmacokinetics of substrate uptake

and distribution in murine brain after nasa! instillation. Phami. Res. 22, 235-244.

• Graff, C.L., Pollack, G.M., 2004. Drug transport at the blood-brain barrier and

the choroid plexus. Curr. Drug. Metab. 5, 95-108.

• Graffl, L.C., Pollock, G.M., 2005b. Nasal drug administration: potential for

targeted central nervous system delivery. J Pharm. Sci. 94, i 187-1195.

CiiaptciT 7 Ftefcreiices


Graiiveau-Renouf, S., Valente, D., Durocher, A., Grognei:, J.M., Ezaii, B., 2000.

Microdialysis study of bromocriptine and its inctaboiites in rat pituitary and

striatum. Eur. J. Drug. Metab. Pharmacokinet. 25: 79-84.

Hans, M.I,.., Lowman, A.M., 2002. Biodegradable ]MPs for drug delivery and

targeting. Curr. Opin. Solid State Mater. Sci. 6 (4), 319-327.

Hanson, L., Roeytenberg, A., Martinez, P.M., Coppes, V.Cl, Sweet, D.C., Rao,

R.J., Marti, D.L,, Hoekman, .I.D., Matthews, R.B., Frey, W.H., Panter, S.S., 2009.

Intrana.sa! deferoxamine provides increased brain exposure and significant

protection in rat isciiemic stroke. J. Pharmacol. Eixp, Tlicr.330, 679-^i6.

Haque, S., M’d, S., P’azil, IVl., Sahni, J.K., Ali, J., Baboota, S., 2012,

Nanomedicines for Brain Targeting: A Patent Review. Reccnt Patent on

Nanomedicines, !(2), 149-161.

Haque, S., Md, S., Fazil, M., Sahni, J.K., Baboota, S., Dang, S., Ali, J,, 2011.

Role of Chitosan Biomaterials in Drug Delivery Systems; A Patent Perspective.

Recent. Pat. Mater. Sci. 4 (3), M 5.

Idaque, S.,Md, S., Alam, I., Sahni, J.K., Ali, J., Baboota, S., 2012. Nano-structure

based drug delivery systems for brain targeting. Drug. Dev. hid. Phann. 38(4),

387-411.

Hu, B„ Pan, C., Sun, Y., Hou, Z., Ye, 11., & Zeng, X. 2008. Optimization of

fabrication parameters to produce chitosan-tripolyphosphatc nanoparticles for

delivery of tea catechins. J. Agri. Food. Chem. 56(16), 7451-7458.

Hu, Y., Jiang, X., Ding, Y., Ge, H., Yuan, Y., Yang, C., 2002. Syndiesis and

characterization of chitosan-poly(acryl!C acid) nanoparticles. Biomaterials.

23(15), 3193 ^ 3201.

Huang, C.H., Kimura, R., Nassar, R.B., Hussain, A., 1985. Mechanism of nasal

absorption of drugs ;Physicochemical parameters influencing the rate of in situ

nasal absorption of drugs in rats. J. Pharm. Sci. 74,608-611.

Huang, Y., Yeh, M., Chiang, C., 2002. Formulation factors in preparing BTM-

chitosan microspheres by spray drying method. Int. J. Pharm. 242, 239-242.

ICFI harmonised tripartite guideline, 2003. Stability testing of New Drug



Substances and Products ()1 A(R2). ICH harmonised tripartite guideline

® ICH harmonised tripartite guideline, 2005. Validation o f analytical procedures:

text and methodology Q2(RI). ICH harmonised tripartite guideline

® Ilium, L., l998.Chitosan and its use as a pharmaceutical excipient, Pharrn. Res.

15, 1326-1331.

® niurn, L., 20()0. Transport of drug from the nasal cavity to the ceivtral nervous

system. Pharni. J. Sci. 11, 1-18.

» Ilium, L , 2004. Is nosc-to-brain transport o f drugs in man a reality? J. Pharni.

Pharmacol. 56, 3--17.

® Ilium, L., Farraj, N.l-'., Davis, S.S., 1994,Chif:osan as a novel na.sal delivery system

for peptide drug.s, Phariii. Res. 11,1186-1189.

® .fackson, J.V., Moss, M.S., Widdop, B., 2005. Clark analytical and toxicologica!

data: in Mojfet, A.C. (Eds). Monograph of bromocriptine mesylate, The

Pharmaceutical Press, London, PP. 401-402.

9 Jia, X., Chen, X., Xu, Y., Han, X., Xu, Z., 2009. Tracing transport of cliitosan

nanoparticles and molecules in Caco~2 ceils by fluorescent labeling. Cabohyd.

Polym. 78, 323-329.

9 Jin, K., Xie, L., Childs, .1., 2000. Cerebral neurogenesis is induced by intranasal

administration o f growth factors. Ann Neurol 5, 405-409.

» Jingou, J., Shilei, H., Weiqi, L., Danjun, W., Tengfei, W., Yi, X. 2011.

Preparation, characterization o f hydrophilic and hydrophobic drug in combine

loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids

Surf B. 83, 103-^107.

« Jung, J., Perrut, M., 2001. Particle design using supercritical fluids: Literature and

patent survey. J. Supercritical Fluids. 20, 179-219.

• Junginger., H.E., 1997. Mucoadhesive polymers in peroral peptide drug delivery

polycarbophil and chitosan arc potent enhancers of peptide transport across

intestinal mucosa in vitro. J. Control. Release. 45, 15-23.

• Kaloti, M., Bohidar, M.B., 2010. Kinetics of coacervation transition versus

nanoparticle formation in Cliitosan-TPF solutions. Colloids. Surf B. Bioint. 81,

165-473.

C hap ter 7 K.t;fererices

Dept of Pliarinaceutics P«ge 186

» Kao, H.D., Traboulsi, A.,, Itoh, S., Dittert, L., Hussain, A., 2000. Enhancement of

the systejnic and CNS specific delivery of L-dopa by the nasal administration of

its water soluble prodrugs. Phann. Res. 17, 978-984.

e Katdare A., Chaiibal M.V., 2006. Excipient Development for Ptiarrnaueutical

Biotechnology and Drug Delivery Systems. Taylor & I^raacis Grou}:), LLC, USA.

© IChaii, S., K., Bobade, N., Yeole, P., Gaikwad, R., 2010. Formulation of

irvtranasa! rniicoadhesive temperature-mediated in siiii gel containing ropinirole

and evaluation of brain targeting efliciency in rats. .1. Drug. Target. 18, 223-234.

e Korscmeyer, RAV., Giirny, R., Docler, E,, Bur, P., Pej3pas, M.A., 198.3.

Mechanism of solute release from porous hydropliilic polymer, hrt. J. F^harm. 15,

25-35.

e Kraig, R.P, Kaminski, M., 2008. Compositions and method for brain specific

targeted delivery of therapeutic agents. US 20080274202 Al.

e Kreuter, .f., Alyautdin, R.N., Karkevich, D.A., Sabel, B.A., 2000. Drug targeting

to the nervous system by nanoparticles. US 6117454.

8 Kreuter, J., Gelperina, S., Maksimenko, ()., Khalanskiy, A., 2009. Polylaetide

Nanoparticles. US 20090263491 A l.

• Kreuter, J., Nanoparticles, in; Swarbrick, J. Boylan, .f.C. (Eds.), Encyclopedia of

Pharmaceutical Technology, 10, 1994, pp. 165-190.

e Kumar, M., Misra, A., Mishra, A.K., Mishra, P., Pathak, K., 2008a.

Miieoadhesive nanoeniulsion-based intranasal drug delivery system of olanzapine

for brain targeting. J. Drug Target, 16(10), 806-814.

• Kumar, M., Misra, A., Babbar, A.K., Mishra, A.K., Mishra, P., Pathak, K., 2008b

Intranasal nanoemulsion based brain targeting ding delivery system of

risperidone. Int. .1. Pharm. 358, 285-91.

• Kvermo, T., Hartter, S., Burger, E., 2006, A review of the receptor binding and

pharmacokinetic properties of dopamine agonists Clin. Ther. 28:1065-1078.

• Kwon, H.Y., Lee, J.Y., Choi, S.W., Jang, ¥ ., Kim, J.H., 2001. Preparation of

PLGA nanoparticles containing estrogen by emuisification-diffusion method.

Colloids Surf. A: Physicochem. Eng. Aspects. 182, 123-130.

C hapter 7 R.eferences


® L a b h a sc tw a r , V .D , R eddy, M.K.,, 20(56. M e th o d and c o m p o s i t io n for in h ib i t in g

rei3erfusion in ju ry in the bratii. US 20060067925 A I .

© Lai, B.C.L., Tsui, J.K.C., 2001. Epidemiology of Parkinson’s disease. British.

Col. Med. J. 43, 133-137

® Leong, K..W., Haller, M.F., Maiavaud, B.A., Lc Visage, C.S., 2004. Systejnic

delivery of compounds through non-invasive bladder administration. US6797704.

Li, Y.P., Pei, Y.Y., Zhou, Z.H., Zluing, X.Y., Gu, Z.f!., Ding, .1, Zhou, J.J., Gao.

X.J., 2001. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-

[alpha] carrier.^. J. Control. Release. 71, 287-296.

Liin, J.H., Kim, S.S., Boo, D.¥L, N o j l , Kang, B.Y., Kim, E.M., Hwang, O,,

Choi, 2009. Protective effect of bromocriptine against BH4-induced Cath.a

cell death involving up-regulation o f antioxidant enzymes. NeiirosGi. Lett. 451,

185-489.

® Lin, X., Zhai, G., Sarad, M., Lohstroh, P.M., 2009. Telomera.se delivery by

biodegradable Nanoparticie. US 20090142408 A l.

• Lins Dantas, P.M., 2011. Pharmaceutical compositions of naiioparticles

containing active ingredients. US20110118364.

® Liu, FL, & Gao, C., 2009. Preparations and properties of ionically crosslinked

chitosan nanoparticles. Polym. Adv. Tech. 20, 613-619.

» Liu, H., Chang, Y., 2001. Preparation and properties o f ionically cross-linked

chitosan nanoparticles. Polym. Adv. Technol. 20 (7), 613-619.

® Liversidge, G., Jenkins, S., Liversidge, E.M., 2011. Injectable nanoparticulate

olanzapine formulations. US7910577.

• Lockman, P. R., Joanna, M. R., Mumper, J. D., Allen, D,, 2004. Nanoparticie

Surface Charges Alter BloocL-Brain Barrier Integrity and Permeability. J. Drug.

Target. 12,635-641.

® Lowary, O.H., Rosebrough, N.J, Farr, A.L., 1951. Protein measurement with the

Folin phenol reagent. J. Biol. Chem. 193, 265--275.

® LueBen, H.L., de Leeuw, B.J., Laogemeyer, M.W., 1997. Mucoadhesive polymers

in peroral peptide drug deliveiy. IV. Polycarbophil and chitosan are potent

C hap ter 7 References

Dept of Pliarm aceutks Page 188

C!liapl:cr 7 Refererices

enhancers of peptide transport across intestinal nnicosac in vitro. J. Control.

Release. 45, 15-23,

® Luo, Y., Zhang, B., Cheng, W.l!., Wang, Q,, 201.0. Preparation, chai’acterization

and evaluation of selenite-loaded chitosan/T'PP naiioparticles witii or vvitliout zein

coating. Carbohyd Polyiii 82, 942-95 L

© Luthra, P.M., Barodia, S.1C., Raghubir, R,, 2009. Antagonism o f haloperidol-

induced swim impairment in 1-dopa and caffeine treated mice: A pre-elinical

model to study Parkinson’s disease, i. Neurosci. Methods. 178, 284-290.

© MacICay, J.A., Deen, .13.F., Szoka, .f.R., Francis, C., 2005. Distribution in brairj of

liposomes after convection enhanetid delivery; modulation by particle charge,

particle diameter, and presence o f steric coating. Brain Research. 1035, 139-153.

® Malodia, 1C., Singh, S.K., Mishra, D.N., Shrivastave, B., 2012. Nanoparticles: An

advance technique for drug delivery. Res. J. Pliarm. Bio. Chem. Sci. 3 (3), 1186-

1208.

Mao, H.Q., .Roy, .K., Troung~Le, V.L., Janes, K.A., Lin, K.Y., Wang, ¥ ., August,

J.T., Leong, K.W., 2001. Chitosaii-DN,A nanoparticles as gene carriers;

synthesis, characterization and transfection efficiency. .1. Control. Relea.se. 70,

399-421.

® Mao, S., Chen, J., Wei, Z., ..Lin 11., Bi, D., 2004. Intranasal administration of

melatonin starch microspheres. Int. J. Pharm. 272, 37-43.

• Md, S., Ahuja, A., Khar, R.K., Baboota, S., Chiittani, K., Mishra, A.K., Ali, J.,

201L Gastroretentive drug delivery system of acyclovir-loaded alginate

mucoadhesive microspheres: Formulation and evaluation. Drug. Deliv. 18 (4)

255-264.

e Md, s., Haqiie, S., Sahni, J.K., Baboota, S Ali, J., 2011. New non-oral drug

delivery systems for Parkinson’s disease treatment. Exp. (3pin. Drug. Deliv.

8(3):359-74.

® Md, S., Kiimar, M., Baboota, S., Sahni, J.K., Ali, J., 2012. Preparation,

Characterization and Evaluation o f Bromocriptine Loaded Chitosan .Nanoparticles

for Intranasal Delivery. Sci. Adv. Mater. 4 (9), 949-960.

Dept of Pliarinaceiitics Page .189

C hap ter References

Mi, F., Shyu, S., Lee, S., & Wong, T., 1999. K in e t ic s tu d y o f chitosan-

tripolyphosphate complex reaction and acid-resistivc p ro p e r t ie s o f the c li i tosa ii..

t r ip o ly p h o sp h a te gel bead s p re p a re d by in - l iq u id cu r in g m e th o d . J. P o ly in Sci. B:

Polyrn Physics. ,37(14), 1 5 5 1 -1 5 6 4 .

Mirkin, C.A., L e ts in g c r , R.L., IVIucic, R .C ., S torlioff , J .J . , Elghaiiian, R., Taton,

T .A ., 2007 . N a n o p a r t ic lc s h a v in g o l ig o n u c le o t id e s a t tac l ied th e re to a n d uses

t h e re ! V) rc . U S 72 5 92 5 2.

M is try , A., S toh iik , S ., I l ium , L., 20 0 9 . N a n o p a r t ic le s Ibr d i re c t n ose - to -b ra ii i

d e l iv e ry o f d rugs, hit. J. P h a n n . 379 , 146-157 .

M itra , S., G aur , U., G h o sh , F’.C., M aitra , A .N . , 2001 .T in i io r ta rg e te d d e l iv e ry o f

encapsulated dextran-doxorubicin conjugate using ch i to sa i i nanoparticles as

carrier . .1. C ontro l. R e lease . 74, 3 i 7 - 3 2 3 .

M itta l , D ., All, A ., M d , S., B a b o o ta , S ., S ah n i , J.K,., A li , J . , 20 1 3 . in s ig h ts in to

Direct nose to brain delivery: Current s ta tus an d ftiture p e r s p e c t iv e . D ru g Deliv.

(In P ress) .

Moffat, A.C., Osselton,M.D., Widdop, B., 2005. Clarice analysis of drugs and

poisons. B"'' Edidon

Morris, G.A., Castile, J., Smith, A., Adams, G.G., Harding, S.E, 2011.The effect

of prolonged storage at different temperatures on the particle size distribution of

tripolyphosphate (TPP)-chitosan nanoparticles. Carbohydr. Polym. 84, 1430-

1434.

Motvi/ani, S.K., Chopra, S., Talegaonkar, S., Kohii, K,, Ahmed, F.Z., Khar, R.K.,

2008. Chitosan-sodium alginate nanoparticles as submieroscopic reservoirs for

ocular delivery: Fornuilation, Opdinization and w vitro characterization. Eur. j.

Pharm. Biopharra. 68, (3), 513-525.

Miiller, R.H. Colloidal Carriers for Controlled Drug Delivery and Targeting. CRC

Press, Boca Raton; 1991 pp. 45-56.

Muller, RH., Jacobs, C., Kayser, O., 2001. Nanosuspensions as

particulate drug formulations in therapy; Rationale for development and what we

can expect for the future. Adv. Drug. Deliv. Rev. 47, 3-19


C hap te r 7 References

Muthane, U.B., Ragothaman, M., Guru raj, (1, 2()07. Epidemiology of Parkinson’s

Disease and Movement Disorders in India; Problems and Possibilities. JAPI. 55,

719-724,

Nagavarma, Yadav, H.K.S., Ayaz, A., Vasudha, L.S., ShivakuiTiar, H.G.,

2012. Different Techniques for preparation of polyrricric nanop;irticles- A

Review. Asian. J. Pharrn. Clin. Res. 5 (3), 16-23.

Nashatizadch, M.M., Lyons, K.Ei., Pahwa, R., 2009. A review of ropiriirolc

proioDged release in i^arkinson’s disease. Clin. Iirterven. Aging. 4, 1,79 -186.

Newrnan, S.P., Wilding, f.R., 1998. Gamrna scintigraphy; an in vivo technique

for assessing the equivalence of inhaled products, int. J. Pharm. 170., 1-9.

Nicolaas, G. M. S., Susanne, O., .lanet, A. FL, Albertus, (}.deBoer., Kjcll,

M.V., Artursson, P., 1997. Chitosans as Absorption Enhancers for Pooriy

Absorbable Drugs 2: Mcchanism of Absorption Enhancement. Pharm. Res. 14

(7), 923-929.

Nicolescu, C., Arama, C., Nedelcu, A., Monciu, C.M., 2010. Phase solubility

studies of the inclusion complexes of repaglinide with p-cyc!odextrin and f]-

cyclodextrin derivatives. E'annacia. 58 (5), 620-628.

Niwa, T., Takeuchi, H., F!ino, T., Kimou, N., Kawashima, Y., 1993. Prepararion of

biodegradable nanoparticles of water-soluble and insoluble drugs vvith D, L-

iactide/ glycolide copolymer by a novel spontaneous eniulsification solvent

diffusion method, and die drug release behavior. .1. Control. Release. 25, 89-98.

Noyes, K., Liu, H, Li, Y., Holloway, R., Dick A.W., 2006. Economic burden

associated with Parkinson’s disease on eldedy medicare beneficiaries. Mov.

Disord. 21(3), 362-372.

Nutt, J.G, Wooten, G.F., 2005. Diagnosis and initial management of Parkinson’s

disease. N. Eng. J. Med. 353, 1021-1027.

Nyholm, D., 2006. Enteral levodopa/carbidopa gel infusion for the treatment of

motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev

Neurother. 6( 10): 1403-1411.


® O’Brien, J.A, Ward, A., .Michels, S.L., Tzivclekis, S., I3raiidt, M.J., 2009.

Economic burden associated with Parkinson disease. Drag Benefit Trends. 21(6),

179-190.

® Ohkawa, H., Ohisiri, N., Yagi, K., 1979. Assay for lipid peroxides in animal

tissues by thiobarbituric acid reaction. Anal. Biochcm. 95, 359-364.

s Pan, Y., Li, Y., Zhao, H., Zheng, J., Xu, IL, Wei, G„ 2002. Bioadhesive

polysaccharide in protein delivery system: Cliitosan nanoparticles improve tlie

intestinal absorption o f insulin in vivo. Int. J. Pharm, 249(1-2), 139..147,

© Papadirnitriou, S., Bikiaris, D., Avgoustakis, K., Karavas, E'., Georgarakis, M.,

2008. Ghitosan nanoparticles loaded with dorzolarnide and pramipexole.,

Carbolnyd Polym 73, 44--54.

» Pardridge, W.M., 1991, Peptide Drug Delivery to the }3rain. Raven Press, New

York, pp. 99--122.

» Pardridge, W,M,, 1999. Blood brain barrier biology and methodology, .1

Neurovirol. 5, 5556-5569.

e Park, U.S., Lee, .I.Y., Cho, S.H., Back, Lee, S.J., 2002. Colon delivery of

prednisolone based on chitosan coated polysaccharide tablets. Arch. Pharm. Res.

25:964-968.

® Pires, A., Fortuna, A., Alves, G., Falcao, A,, 2009. Intranasal Drug Deliveiy:

How, Why and What for? J. Pharm. Sci. 12 (3), 288 3 H .

® Prokop, A. 2004. Micro-particulate and nano-particulate polymeric delivery

sy.stem US20046726934.

9 Prokop, A., 2003. Drug delivery system exhibiting permeability control

US20036589563.

® Pujara, C.P., Shao, Z., Duncan, M.R., Mitra A.K., 1995. Effects of formulation

variable.s on nasal epithelial cell integrity: Biochemical evaluations, Int. J, Phcirm.

114,197-203

® Qi, L., Xu, Z-, .fiang, X., Hu, C., Zou, X., 2004. Preparation and antibacterial

activity of chitosan nanoparticles. Carbohyd. Res. 339, 2693-2700.



® RaoJ,P., GcckeJer, K.E., 201!. Polymer nanoparticlcs: f^reparatioii techniques

and size control parameters, Prog. Poiym. Sci. 36 (7), 887-913.

• Reddy, J.R. 2010, Preventive anti therapeutic vaccinc for A!:zheimer’s disease. US

20(00!73004.

® Reddy, L , Sharma, R.., Chuttani, K., Mislira, A., Murthy, R., 2004. Etoposide-

incorporated tripahnitin narioparticles witii different surface charge: fomrulation,

characterization, radiolabcling, and biodistribution Studies. AAPS J 6(3), 23.

® Reddy, R.G., Erathodiyil, N„ 2005. Degradable nanoparticles. US20050I 96343,

e Reis, C.P., Neufekl, R.J., Ribciro, A.J., Veiga, F., 2006. Nanoencapsulation I.

Methods for preparation of drug-loaded polymeric nanoparticles Nanomed:

Manotech, Bio, and Med. 2, 8~ 2 1.

e Reger, M.A., Watson, G.S., Frey, W.H., 2006. Effects of intranasal insulin on

cognition in memory-impaired older adults: modulation by APOE genotype.

Neurobiol Aging. 27, 451-458.

9 Reverchon, E., Adami, R., 2006. Nanoniaterials and superci'itica! fluids. J.

Supercritical Fluids. 37, 1-22.

® Riggs, J. E., 2001. Age specific rate of neurological disease. Neurobio] Aging. 1:3-

n

® Ringe, K., Radunz, H.E., Kubasch, .1., 2009. Nanoparticles Designed for Drug

Delivery. US 20090297613 AL

» Rolland, .I.P., Maynor, B.W., Euliss, L.E., Exner, A.E., Denison, G.M.,

DeSimone, J.M., 2005. Direct fabrication and harvesting of monodisperse, shape-

specific nanobiomateriais. J. Am. Chem. Soc. 127, 10096-10100.

® Saboktakin, M.R., Tabatabaee, R.M., Maharramov, A., Ramazanov, M.A., 2010.

Design and characterization o f chitosan nanoparticles as delivery systems for

paclita.x,el Carbohyd. Polym. 82, 466-471.

» Sadeghi, A., Dorkoosh, F.A., Avadi, M.A., Saadat, P Rafiee-Tehrani, M,,

Jiinginger, H.E., 2008. Preparation, characterization and antibacterial activities of

chitosan, N-trimethyl chitosan (TMC) and N~diet:hylmethyl chitosan (DEMC)

nanoparticlcs loaded v/ith insulin using both the ionotropic gelation and

polyelectrolyte complexation methods. Int. J. Pharm. 355, 299-306.

Cliapter 7 References

Dept of Pliarmsceutics Page 193

® Sakane, T., Akizuki, (V!,, Taki, Y., Yamasiiita, S ., Sezaki, H., Naclai, T., 1995.

Direct drug transport from the rat nasai cavity to the cerebrospinal fluid: the

relation to the molecular weight of drugs. J Pharrn Pliarmacol, 47 , 379-381.

® Sakane, T., Akizuki, M., Taki, Y., Yamasiiita, S., Se?:aki, H., Nadai, T., 1991. Tlie

transport o f a drug to the cerebrospinal fluid directly from the nasal cavity: the

relation to the lipophilicity of the drug. Cheni Pharm Bull. 39, 2456--245H.

e Sakane, T., Akizuki, M., Taki, Y., Yamasiiita, S., Sezaki, H., Nadai, T., 1994.

transport from tlie rat nasal cavity to tlic cercbrospina! fluid; the relation f:c> tlie

dissociation of the drug. .1. Pharm. Pharmacol. 46, 378-379.

® Salvador, A., Dubreuil, D., Denouef, J., Millerioux, L., 2005. Sensitive metliod for

the quantitative determination of brosnocriptine in human plasma by liquid

chromatography^^landem mass spectrometry. J. Chromatography. 13. 820, 237-242.

e Samson, G., de la Calera, A.G., Dupuis-G irod, S.,Faure, F., Decullier, E., 2011.

Ex vivo study of bevacizurnab transport through porcine nasal mucosa. Eiir. J.

Pharm. Biopharm. 80 (2), 465-469

9 Sarmento, B., Ferreira, D., Veig, P., Ribeiro, A., 2006. Characterization of insidin-

loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC

and FTIR studies. Carb Polym. 66, 1-7

® Schapira, A.Fl.V., 2005. Present and future drug treatment for Parkinson’s

disease. J. Neurol. Neurosurg. Psychiatry. 76, 1472-4478.

a Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein bound and nonprotein

sulftiydryl group in tissue u'ith Ellnian’s reagent. Anal. Biochern. 25,192-205.

® Segal, M.B., 2000. The choi’oid plexuses and the barriers between the blood and

the cerebrospinal fluid. Ceil Mol Neurobiol. 20, 183--196.

® Seju, U., Kumar, A., Sawant, K.K., 2011. Development and evaluation of

olanzapine-loaded PJXiA nanoparticles for uose-to-brain deliveiy: in vitro and in

vivo studies. Acta. Biomater. 7, 4169-4176.

• Shah, S., Pal, A., Kaushik, V.K., Devi. S., 2009. Preparation and characterization

of venlafaxine hydrochloride-loaded chitosan nanoparticles and in vitro release of

drug. Applied. Polym. Sci. 112, 2876-2887.

Clisipter 7 References


e Shu, X.Z., Jhu, K.J., 2002. The itifliience of niultivalcnt |)hosphat:e structure on

the properties o f ioriicaHy cross-linked cliitosan filiiis for cootroiled drug release,

Eur. J. Pharm, Biopharrn,. 54, 235..243.

e Singh, N., Piliay, V., Choonara, Y.E., 2007. Advances in the treatment: of

Parkinson’s di.sease. Prog. NeurobioL 81, 29-44.

» Smith, E., Wood, M., Dornish., 2004. Effect of cliitosan on epithelial cell tight

junctions. Pharm. Res. 2 i, 43-49.

© Soane, R.J., Frier, M., Perkins, A.C., Jones, N.S., Davis, S.S., Illiini, L., 1999.

fZvaluation of the clearance characteristics of bioadhesive systems in huirians. Int.

.1. Phann. 178, 55-65.

® Soane, R..I., Hinchcliffe, M., Davis, S.S., Ilkrm, L., 2001. Clearance characteristics

of chitosan based formulations in the sheep nasal cavity, hit. I. Phann. 217, '183-

191.

® Spector, R., 2000. Drug transport in the rnammcilian central nervous system;

multiple complex systems. A critical analysis and commentaiy. Pharmacology.

60, 58-73.

® Sun, Y., Mezian, M., Pathak, P., Qu, L,, 2005. Polymeric nanoparticles from rapid

expansion of supercritical fluid solution. Chemistry. 11, 1366-1373.

e Sung, 11.W., Peng, S.F, Tu, H., 2011. Nanoparticles for protein drug delivery. US

7879312 BL

® Sung, H.W., Tu, H., 2011. Nanoparticles for protein drug delivery. US 7910086

Bl.

e Sung, H“W., Lin, Y., Chen, M., Tu, FL, 2009. Nanoparticles for monoclonal

antibody delivery, LJS7541028.

• Tang, E.S.K., M. Huang, M., Lim L.Y., 2003. liltrasonication of chitosan and

chitosan nanoparticles. Int. J. Pharm. 265:103-114.

e Tantishaiyakul, V., Kaenopparat, N., Ingkatavvoniwong, S., 1999. Properties of

solid dispersions of piroxicam in polyvinylpyrrolidone. Int. i. Pharm. 181: 143-

151.

Ciiaptei' 7 References

Dept of Pharmaceutics Fage 195

C Is ap te r 7 Re fe re n ces

Thanou, M., Verhoef, J.C., Juniginger, H.E., 2001. Orai drug absoiptioti

enhancement by chitosaii and its derivatives. Adv. Drug. Deliv. Rev. 52, 117-126.

Thorne, R.G., Proiik, J., Padmanabhan, V., 2004. Delivery o f insuiin-likc growth

factor to the rat brain and spinal cord along olfactory and trigeminal patlivvays

following intranasal administration. Neiirosciencx;. 127, 4 8 1-496.

Tokuinitsu, H., Ichikawa, Y., Fukumori., 1999. Chitosan-gadopeDtetic acid

complex nanoparticlcs for gadolinium neutron capture therapy o f cancer:

preparation by novel emidsion-droplet coalescence technique and characterization.

Pharm.Res, 16, 1830-1835.

Tou(on.se, A., Sufh'van, A.M., 2008. Progress in Ptu'kinson’s disease— Where do

we stand? Prog. Neurobioi. 8.5, 376“-'392.

Trapani, A., De Giglio, E., Cafagna, D., Den ora, N., Agrimi, G., Cassano, T.,

Gaetani, S., Cnomo, V., Trapani, G., 2011. Characterization and evaluation of

chitosan nanoparticlcs for dopamine brain delivery. Int. .1. Pharm. 419, 296- 307.

Trevitt, J., Vallance, C., Harris, A., Goode, T., 2009. Adeno.sine antagonists

reverse the cataleptic effects of haloperidol: Implications for the treatment of

Parkinson's disease. Pharmacol. Biocheni. Behav. 925, 21--527.

Tsai, Y.M., Chien, C.F., Lin, L.C., Tsai, T.H., 2011. Curcumin and its nano

formulation: The kinetics of tissue distribution atid blood-brain barrier

penetration. Int. J. Pharm. 416, 3 3 1- 33<S.

Turos, E., Cormier, R., Kyle, D.E., 2010. Polyaci7 late Nanoparticle Drug

Delivery. US 20100278920.

United State of Pharmacopoeia, 2006. United States Pharmacopoeia! Convention,

Rockville, USA.

Upadhyay, K.K., .Bhatt, AN., Castro, E., Mishra, AK., Chuttani, K.,

Dwarakanath, BS., Schatz, C., Le, Meins JF., Misra, A., Lecommandoux, S.,

2010. In vitro and In vivo evaluation of docetaxel loaded biodegradable

polymersomes. Macromol. Biosci. 10 (5), 503-512.

Vautier, S., Lacomblez, L,, Chacun, H,, Picard, V., Gimenez, F., Farinotti, R.,

Fernandez, C., 2006. Interactions between the dopamine agonist, bromocriptine


C hap ter 7 References

and the efflux protein, P-glycopi'otein at tlie blocxi-braiii barrier iis the iriouse.

Eur. .1. Pharm. Sci, 2 7, 167..174.

Venna, R., Nehru, B,, 2009. Evffect of centroplieiioxine againsl rotenone-iiKliiced

oxidative stress in an anima! model of Parkinson’s disease. Neurochem. Int. 55,

369<VI5

Vila, A., Sancliez, A., Tobio, M., Caivo, P., Alonso, M.J., 2002. Design of

b io d e g ra d a b le p a r t ic le s fo r p ro te in deli very, .f. Comtrol. R e l . 78 (1 -3 ) , 15-24.

Vyas, T.K., Babbar, A.K., Sharma, R.K., Singh, S., Misra, A., 2006. Preliminary

Brain-targeting Studies on Intranasai mucoadhesivc microeiiiiiisions of

sumatriptan. AAPS Pharmscitech. 7, (I), !-8.

Vyas, T.K., Babbar, A.K., Siiarma, R.K., Singh, S., Misra, A,, 2006. Intranasai

miicoadhesive microemulsions of clonazepam: preliminary studies on brain

targeting. J. Pharm. Sci. 95 (3), 570-580.

Vyas, T.K., Shahiwala, A., Marathe, S., Misra, A., 2005. lutranasal drug delivery

for brain targeting, Curr. Drug. Deliv. 2, 165-475.

Wang, F., Jiang, X., Lu, VV., 2003. F’rofiles of methotrexate in blood and CSF

following intranasai and intravenous administration to rats. Int. J. Pharm. 263, 1-

7.

Wang, X., Chi, N., Tang, X., 2008. Preparation of estradiol chitosan nanoparticles

for improving nasal absorption and brain targeting 15ur. J. Phann. Biopharm. 70,

735-40.

Wang, Z.H., Wang. Z.Y., Sun, C.S., Wang, C.Y., Jiang, T. Y., Wang, S.L., 2010.

Triraethylated chitosan-conjugated PLGA naiioparticles for the delivery of drugs

to the brain. Biomaterials. 31(5), 908-915.

Wei, G., Wang, D., Lai, H., Parmentier, S., Wang, Q., F^anter, uS.S., Frey, W.H.,

Ying, W., 2007. Intranasai administration of a PARG inhibitor profoundly

decreases ischemic brain injury. Front. Biosci. 12, 4986-4996.

Wen, Z., Yan, Z., Hu, K., Pang, Z., Cheng, X., Guo, L., Zhang, Q., Ziang, X.,

Fang, L., Rai, R., 2011. Odorranalectin-conjugated nanoparticles; Preparation,

brain delivery and pharmacodynamic study on Parkinson's disease following

intranasai administration. J. Control. Release, 151, 131-138.


C hapter 7 References r " z *- ' “ -L*zr ” - ^7 T" ” V

® Westin, U., Piras, E„ Jansson, B., Bergstrom, U., Dahlin, M., J3rittebo, E., Bjork,

E., 2005. T ra n s fe r o f m o rp h in e a lo n g tlie o l fa c to ry p a t l iw a y to tlie cerilj;al oervotis

sy s te m a f te r na sa l a d m in is t r a t io n to rodents. Eur. J. Pharrn. Sci. 24 (5 ) , 5 6 5 -5 7 3 .

® Wilson, B., Samanta, M.K., Santlii, K., Sarnpath. K., Ramasamy, IVL, Surcsli, B.,

2010. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug

tacrine. Nanomed; Nanotech. Bio. and Med. 6(1), 144-152.

s Winter, Y., Campenhausen, S.V., Popov, G., Reese, J.P., Gueicht, A., 2009. Costs

of iilness in a Russian cohort of patients with Parkinson’s disease.

Pharmacoeconomics. 27(7), 571-584.

© Wli, H., Hu, K., .hang, X., 2008. From nose to brain; understanding transport

capacity and transport rate of drugs. Expert: Opin. Drug Deliv. 5 (10), 1159-1168.

Wu, T.H., Yen, F.L., Lin, L.T., Tsai, T.R., Lin, C.C., Charn, T.M., 2008.

Preparation, physicochemical characterization, and antioxidant effects of

quercetin nanoparticles, hit. J. Pharm. 346(1-2), 160-168.

® WUj Y., Yang, W., Wang, C., Hu, ,1., Fu, S, 2005. Chitosan NPs as a novel

delivery system for ammonium giycyrrhizinate. int. J. Pharm. 295, 235~-245.

e Xu, Y., & Du, Y. 2003. Effect of molecular structure o f chitosan on protein

delivery properties of chitosan nanoparticles, hit, J. Pharrn. 250(1), 215 -226.

® Yin, Y., Chen, D., Qiao, M., Lu, Z., & Hu, H. 2006, Preparation and evahiation of

lectin-conjugated FLGA nanoparticles for ora! delivery of thyraopentin. J.

Control. Release, 116, 337-345.

Ying, W., Wei, G., Wang, D., Wang, Q., Tang, X., Shi, J,, Zhang, P., Lu, H.,

2007. Intranasal administration with NAI3+ profoundly decreases brain injury in a

rat model o f transient focal ischenu'a. Frorst. Biosci. 12, 2728-2734.

® Yu, S., Zhao, Y., Wu, F., Zhang, X., Lii, W,, Zhang, H., Zhang, Q., 2004. Nasal

insulin delivery in the chitosan solution; in vitro and in vivo studies, hit. J. Pharm.

281, 11-23.

® Yu, Y.P., Xit, Q.Q., Zhang, Q., 2005. Intranasal recombinant hiiman

erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett. 387, 5~

10.

Dept of Phariiiaceiitics PJige 198

« Zhang G, Sue L, Aiig P., 2008, Polyethyiene glyc()l-gr;ifted clrit:osan iianoparticies

nasai administration of insulin. J Pharm Sci, 85, 1-! L

e Zhang, L., Kosaraju, S. L., 2007. Kopolymeric delivery system for controlled

release of poiyphenolic antioxidaiits. Eiir. Polyrn J. 43(7), 2956-2966.

® Zhang, M., Olson, Ellenbogen, R.G., Veiseh, 0 ., Sun, C„ Gunn, J.W., 2007,

Chlorotoxin-labeled nanoparticle compositions and methods for targeting primary

brain tumors. US20070154965 A l,

® Zhang, Q., Jiang, X., Jiang, W., Lii, W., Su, L., Shi, Z., 2004. Preparation of

nimodipine loaded microemulsion ;for intranasal delivery and evaluation of the

targeting efficiency to brain. Int. J, Pharm. 275, 85-96,

® Zhang, Q., Shen, Z., Nagai, T ., 2001. Prolonged hypoglycaemic effect o f insufin-

loaded polybutylcyanoacrylate nanoparticles after piilrnonary administration to

normal rats. Int. J. Phami. 218, 75-80

e Zhou, S.B., Deng, X.M., Li, X.H., 2001. Investigation on a novel core-coated

microspheres protein delivery system. J. Control. Rel. 75, 27-36.

C hap ter 7 .References


5-28. -...

Documents